Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

View Full Paper
Ask AI
Bookmark
Share

Authors

INIoannis Ntanasis-StathopoulosNKNikolaos KanelliasDFDespina Fotiou

Discussion

Loading...

Member takes

Overview

Assessment reveals treatment response correlates with progression-free survival in newly diagnosed multiple myeloma patients.

Key Points

  • Sustained MRD negativity correlates with prolonged progression-free survival in multiple myeloma patients.
  • Patients undergoing first line treatment exhibited significant variations in MRD status and outcomes.
  • Analysis includes 323 newly diagnosed multiple myeloma patients evaluated for minimal residual disease.
  • Results highlight the importance of MRD assessment in predicting patient prognosis and treatment decisions.

Cite This Study

Ntanasis-Stathopoulos et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7e7https://doi.org/10.1182/blood-2025-2216
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  2. 2Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma2025 · 1 citations
  3. 3What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma2025
  4. 4Real-world study on discontinuation strategies after MRD negativity in multiple myeloma patients2025
  5. 5Delayed and sustained minimal residual disease response predictsfavorable outcomes in newly diagnosed multiple myeloma2025